Related Experiment Video

Updated: Aug 18, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Comorbid Inflammatory Diseases in Behçet's Disease: A Multicenter Large Cohort Study

Emine Büşra Ata1, İbrahim Yahya Çakır2, Semiha Köroğlu3

  • 1Department of Internal Medicine, Division of Rheumatology, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkiye.

International Journal of Rheumatic Diseases
|August 17, 2026
PubMed

Insights

Behçet

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Behçet's disease (BD) is a chronic, multisystem immune-mediated vasculitis.
  • Inflammatory comorbid (IC) diseases can significantly impact BD's clinical course.
  • Limited research exists on the prevalence and spectrum of IC diseases in BD patients.

Purpose of the Study:

  • To determine the prevalence of inflammatory comorbid diseases in Behçet's disease.
  • To characterize the clinical spectrum of these comorbidities in BD patients.
  • To identify factors associated with the presence of IC disease in BD.

Main Methods:

  • Retrospective analysis of 1591 BD patients from five tertiary centers.
  • Systematic collection of demographic, clinical, and laboratory data.
  • Evaluation of disease activity using the Behçet's Disease Current Activity Form (BDCAF).

Main Results:

  • 15.3% of BD patients had identified inflammatory comorbidities.
  • Most common comorbidities included axial spondyloarthritis (7.2%), familial Mediterranean fever (2.4%), and hidradenitis suppurativa (2.3%).
  • Patients with IC disease showed increased anti-TNF treatment use; older age and longer disease duration were associated with IC disease.

Conclusions:

  • Behçet's disease frequently co-occurs with other inflammatory conditions.
  • The presence of IC disease may influence treatment decisions, including anti-TNF therapy.
  • Clinicians should actively screen for and manage inflammatory comorbidities in BD patients.
Abstract

Keywords:
Behçet's diseaseautoinflammatorycomorbidityhidradenitis suppurativaspondyloarthritis

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...